atropine has been researched along with clozapine in 56 studies
Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
---|---|---|---|---|---|
26,711 | 1,259 | 1,697 | 9,691 | 747 | 3,148 |
Protein | Taxonomy | atropine (IC50) | clozapine (IC50) |
---|---|---|---|
Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
D | Rattus norvegicus (Norway rat) | 1.066 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
D | Bos taurus (cattle) | 4.09 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (23.21) | 18.7374 |
1990's | 8 (14.29) | 18.2507 |
2000's | 16 (28.57) | 29.6817 |
2010's | 18 (32.14) | 24.3611 |
2020's | 1 (1.79) | 2.80 |
Authors | Studies |
---|---|
Baldy, WJ; Davis, CB; DiStefano, DL; Elgin, RJ; Fedde, CL; Kesslick, JM; Martin, GE; Mathiasen, JR; Scott, MK; Shank, RP | 1 |
Andrews, PR; Craik, DJ; Martin, JL | 1 |
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Asper, H; Bürki, HR; Ruch, W; Sayers, AC | 2 |
Richelson, E | 1 |
Korf, J; Westerink, BH | 1 |
Closse, A; Hauser, D | 1 |
Bürki, HR; Sayers, AC | 1 |
Marsden, CA; Rivest, R | 1 |
Bolden, C; Cusack, B; Richelson, E | 1 |
Nielsen, EB | 1 |
Mott, J; Sherman, AD | 1 |
de Belleroche, JS; Neal, MJ | 1 |
Baez, LA; Burt, DK; Crowner, ML; Hungerford, SM | 1 |
Herrling, PL; Misbach-Lesenne, B | 1 |
Palumbo, PA; Winter, JC | 1 |
Cawley, TA; Luthin, GR; Ruggieri, MR; Shickley, TJ | 1 |
Brent, PJ; Chahl, LA | 1 |
Csernansky, JG; Nemecek, D; Rastogi-Cruz, D | 1 |
Maullu, C; Olianas, MC; Onali, P | 1 |
Antonello, C; Tessier, P | 2 |
Brar, JS; Chengappa, KN; Kirshner, MA; Levine, J; Parepally, H; Pollock, BG; Zoretich, RA | 1 |
Ash, D; Comley, C; Galletly, C | 1 |
Dahl, E; Dewan, V; Ramaswamy, S; Sharma, A | 1 |
Bourguignon, JJ; Carnicella, S; Mongeot, A; Oberling, P | 1 |
Burke, J; Cox, M; Khan, A; Mustafa, FA; Sherif, S | 1 |
Capurso, NA; Matos Santana, TE; Ranganathan, M; Yoon, G | 1 |
de Alvarenga, KAF; de Rezende, VB; Romano-Silva, MA; Rosa, DV; Sacramento, EK; Souza, BR | 1 |
De Hert, M; van der Poorten, T | 1 |
Lambert, T; Mubaslat, O | 1 |
2 review(s) available for atropine and clozapine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Sublingual use of atropine for clozapine-induced sialorrhoea: literature review and two case reports].
Topics: Administration, Sublingual; Atropine; Clozapine; Humans; Sialorrhea | 2019 |
2 trial(s) available for atropine and clozapine
Article | Year |
---|---|
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.
Topics: Adult; Antipsychotic Agents; Atropine; Autonomic Nervous System Diseases; Benzodiazepines; Cholinergic Antagonists; Clozapine; Female; Humans; Male; Muscarinic Antagonists; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Radioligand Assay; Receptors, Muscarinic | 2000 |
The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomised placebo-controlled trial.
Topics: Administration, Sublingual; Adult; Antipsychotic Agents; Atropine; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Saliva; Salivation; Sialorrhea; Treatment Outcome | 2020 |
52 other study(ies) available for atropine and clozapine
Article | Year |
---|---|
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Dose-Response Relationship, Drug; Piperazines; Rats; Receptors, Dopamine; Receptors, Serotonin; Structure-Activity Relationship | 1989 |
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.
Topics: Animals; Antipsychotic Agents; Atropine; Basal Ganglia Diseases; Clozapine; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Homovanillic Acid; Male; Parasympathetic Nervous System; Physostigmine; Rats; Receptors, Dopamine; Receptors, Muscarinic | 1976 |
Tricyclic antidepressants and histamine H1 receptors.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Atropine; Benztropine; Cells, Cultured; Clozapine; Cyproheptadine; Desipramine; Doxepin; Haloperidol; Histamine H1 Antagonists; Hydroxyzine; Imipramine; Mice; Neoplasms, Experimental; Neuroblastoma; Nortriptyline; Protriptyline; Receptors, Histamine; Receptors, Histamine H1; Receptors, Muscarinic | 1979 |
Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain.
Topics: Aminooxyacetic Acid; Animals; Atropine; Brain; Brain Chemistry; Clozapine; Corpus Striatum; Fenclonine; Haloperidol; Homovanillic Acid; Limbic System; Male; Morphine; Oxotremorine; Phenylacetates; Physostigmine; Pimozide; Probenecid; Rats; Substantia Nigra; Trihexyphenidyl | 1975 |
3H-Clozapine binding to rat brain membranes.
Topics: Animals; Atropine; Brain; Butaclamol; Clozapine; Dibenzazepines; In Vitro Techniques; Male; Membranes; Rats; Stereoisomerism | 1978 |
[Effects of anticholinergics and clozapine on the activation of the striatal dopaminergic system in the rat by haloperidol. Pharmacological findings (author's transl)].
Topics: Animals; Apomorphine; Atropine; Clozapine; Corpus Striatum; Dibenzazepines; Dopamine; Drug Synergism; Haloperidol; Humans; Movement Disorders; Rats; Receptors, Drug; Stereotyped Behavior | 1976 |
[Effects of anticholinergics and clozapine on the activation of the striatal dopaminergic system in the rat by haloperidol. Neurochemical findings (author's transl)].
Topics: Animals; Atropine; Clozapine; Corpus Striatum; Dibenzazepines; Dopamine; Drug Synergism; Drug Tolerance; Haloperidol; Homovanillic Acid; Rats; Receptors, Drug | 1976 |
Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Clozapine; Corpus Striatum; Dopamine; Electric Stimulation; Extracellular Space; Haloperidol; Male; Nucleus Accumbens; Parasympatholytics; Rats; Rats, Inbred Strains; Scopolamine | 1991 |
Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells.
Topics: Animals; Atropine; Cell Line; Chlorpromazine; Clozapine; Cricetinae; Cricetulus; Female; Humans; Parasympatholytics; Quinuclidinyl Benzilate; Receptors, Muscarinic; Thioridazine | 1991 |
Cholinergic mediation of the discriminative stimulus properties of clozapine.
Topics: Animals; Atropine; Clozapine; Dibenzazepines; Discrimination, Psychological; Male; Parasympathetic Nervous System; Rats; Rats, Inbred Strains; Reinforcement Schedule; Scopolamine | 1988 |
Direct effect of neuroleptics on glutamate release.
Topics: Amygdala; Animals; Antipsychotic Agents; Atropine; Avoidance Learning; Butaclamol; Calcium; Chlorpromazine; Clozapine; Glutamates; Glutamic Acid; Glutamine; Haloperidol; In Vitro Techniques; Male; Rats; Synaptosomes | 1984 |
The contrasting effects of neuroleptics on transmitter release from the nucleus accumbens and corpus striatum.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Atropine; Chlorpromazine; Clozapine; Corpus Striatum; Dopamine; Female; Haloperidol; Neurotransmitter Agents; Nucleus Accumbens; Potassium; Rats; Rats, Inbred Strains; Receptors, Cholinergic; Receptors, Dopamine; Septal Nuclei; Thioridazine | 1982 |
Postnatal development of a cholinergic influence on neuroleptic-induced catalepsy.
Topics: Aging; Animals; Atropine; Brain; Butyrophenones; Clozapine; Dibenzazepines; Dose-Response Relationship, Drug; Female; Male; Motor Activity; Muridae; Reaction Time; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Muscarinic; Spiperone | 1982 |
Effects of clozapine in a selective muscarinic bioassay and on single cells of the rat hippocampus.
Topics: Acetylcholine; Animals; Astacoidea; Atropine; Carbachol; Cats; Clozapine; Dibenzazepines; Drug Interactions; Electrophysiology; Female; gamma-Aminobutyric Acid; Hippocampus; In Vitro Techniques; Male; Muscle Contraction; Rats; Receptors, Cholinergic; Receptors, Muscarinic | 1982 |
Interactions of clozapine with the stimulus effects of DOM and LSD.
Topics: Animals; Atropine; Clozapine; Discrimination, Psychological; DOM 2,5-Dimethoxy-4-Methylamphetamine; Generalization, Stimulus; Lysergic Acid Diethylamide; Male; Muscarinic Antagonists; Rats; Rats, Inbred F344; Serotonin Antagonists | 1994 |
Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors.
Topics: Animals; Antipsychotic Agents; Atropine; Cell Membrane; Clozapine; Corpus Striatum; Fluphenazine; Male; Myocardium; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Time Factors; Urinary Bladder | 1993 |
Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Atropine; Behavior, Animal; Clozapine; Dizocilpine Maleate; Female; Guinea Pigs; Ketamine; Kinetics; Male; Morphine; Motor Activity; Naloxone; Phenazocine; Raclopride; Radioligand Assay; Receptors, sigma; Remoxipride; Salicylamides; Substance Withdrawal Syndrome | 1993 |
Atropinism may precipitate neuroleptic malignant syndrome during treatment with clozapine.
Topics: Adult; Atropine; Autonomic Nervous System Diseases; Clozapine; Humans; Male; Neuroleptic Malignant Syndrome; Parasympathetic Nervous System; Schizophrenia | 1993 |
Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells.
Topics: Animals; Antipsychotic Agents; Atropine; Binding Sites; Cell Membrane; CHO Cells; Cloning, Molecular; Clozapine; Cricetinae; Cyclic AMP; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Inositol Phosphates; Muscarinic Agonists; Muscarinic Antagonists; N-Methylscopolamine; Receptor, Muscarinic M1; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Receptors, Muscarinic; Sulfur Radioisotopes | 1999 |
Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect.
Topics: Antipsychotic Agents; Atropine; Clozapine; Humans; Mydriatics; Parasympatholytics; Sialorrhea; Treatment Outcome | 1999 |
Use of atropine eye drops for clozapine induced hypersalivation.
Topics: Adult; Atropine; Chronic Disease; Clozapine; Female; Humans; Ophthalmic Solutions; Schizophrenia; Sialorrhea | 2000 |
Clozapine and sialorrhea: update.
Topics: Administration, Intranasal; Administration, Sublingual; Atropine; Clozapine; Humans; Ipratropium; Sialorrhea | 2001 |
Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea.
Topics: Administration, Oral; Antipsychotic Agents; Atropine; Clozapine; Humans; Male; Middle Aged; Muscarinic Antagonists; Ophthalmic Solutions; Schizophrenia, Paranoid; Sialorrhea | 2004 |
Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats.
Topics: Animals; Antipsychotic Agents; Atropine; Benzodiazepines; Clozapine; Conditioning, Classical; Drug Interactions; Haloperidol; Male; Muscarinic Antagonists; Olanzapine; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2010 |
Neuroleptics: necrotising enterocolitis.
Topics: Antipsychotic Agents; Atropine; Benzodiazepines; Clozapine; Drug Therapy, Combination; Enterocolitis, Necrotizing; France; Humans; Risperidone; Sulpiride | 2009 |
Sublingual atropine for the treatment of severe and hyoscine-resistant clozapine-induced sialorrhea.
Topics: Administration, Sublingual; Antipsychotic Agents; Atropine; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Humans; Male; Middle Aged; Muscarinic Antagonists; Schizophrenia; Scopolamine; Sialorrhea; Treatment Outcome | 2013 |
Sublingual atropine in the treatment of clozapine-induced sialorrhea.
Topics: Administration, Sublingual; Adult; Antipsychotic Agents; Atropine; Clozapine; Humans; Male; Middle Aged; Muscarinic Antagonists; Psychotic Disorders; Schizophrenia; Sialorrhea | 2017 |
Effects of antipsychotics on intestinal motility in zebrafish larvae.
Topics: Animals; Antipsychotic Agents; Atropine; Clozapine; Drug Evaluation, Preclinical; Gastrointestinal Motility; Gastrointestinal Tract; Haloperidol; Larva; Muscarinic Antagonists; Risperidone; Zebrafish | 2017 |